Innocare Pharma Ltd (9969)

Currency in HKD
14.70
+0.62(+4.40%)
Closed·
9969 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.1014.92
52 wk Range
8.8620.62
Key Statistics
Bid/Ask
14.68 / 14.70
Prev. Close
14.08
Open
14.41
Day's Range
14.1-14.92
52 wk Range
8.86-20.62
Volume
9.12M
Average Volume (3m)
8.43M
1-Year Change
35.9073%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9969 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.33
Upside
+38.31%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Innocare Pharma Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Compare 9969 to Peers and Sector

Metrics to compare
9969
Peers
Sector
Relationship
P/E Ratio
36.0x−16.6x−0.4x
PEG Ratio
0.100.050.00
Price/Book
3.6x6.4x2.6x
Price / LTM Sales
10.4x14.1x3.2x
Upside (Analyst Target)
36.8%34.6%46.7%
Fair Value Upside
Unlock2.1%7.6%Unlock

Analyst Ratings

9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.33
(+38.31% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Buy22.89+55.71%20.59MaintainOct 09, 2025
Morgan Stanley
Hold19.60+33.33%8.25MaintainSep 22, 2025
Goldman Sachs
Buy20.59+40.07%18.41MaintainAug 20, 2025
UBS
Buy25.20+71.43%13.60MaintainJul 24, 2025
Goldman Sachs
Buy18.41+25.24%12.72MaintainJul 09, 2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.02 / --
Revenue / Forecast
383.89M / --
EPS Revisions
Last 90 days

9969 Income Statement

FAQ

What Is the Innocare (9969) Stock Price Today?

The Innocare stock price today is 14.70 HKD.

What Stock Exchange Does Innocare Trade On?

Innocare is listed and trades on the Hong Kong Stock Exchange.

What Is the Stock Symbol for Innocare?

The stock symbol for Innocare is "9969."

What Is the Innocare Market Cap?

As of today, Innocare market cap is 29.75B HKD.

What Is Innocare's Earnings Per Share (TTM)?

The Innocare EPS (TTM) is 0.38.

From a Technical Analysis Perspective, Is 9969 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Innocare Stock Split?

Innocare has split 0 times.

How Many Employees Does Innocare Have?

Innocare has 1176 employees.

What is the current trading status of Innocare (9969)?

As of Apr 24, 2026, Innocare (9969) is trading at a price of 14.70 HKD, with a previous close of 14.08 HKD. The stock has fluctuated within a day range of 14.10 HKD to 14.92 HKD, while its 52-week range spans from 8.86 HKD to 20.62 HKD.

What Is Innocare (9969) Price Target According to Analysts?

The average 12-month price target for Innocare is 20.33 HKD, with a high estimate of 22.15112946 HKD and a low estimate of 17.38676757 HKD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +38.31% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.